XPHvsARKGETF Comparison
VS
State Street SPDR S&P Pharmaceuticals ETF (XPH) belongs to the US Health Care segment. ARK Genomic Revolution ETF (ARKG) is part of the BioTech & Genomics segment. Both ETFs have the same top 1 sector exposures: Healthcare. XPH is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.75% for ARKG. XPH is up 14.29% year-to-date (YTD) with +$186M in YTD flows. ARKG performs better with 76.72% YTD performance, and +$90M in YTD flows. Run a side-by-side ETF comparison of XPH and ARKG below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XPH vs ARKG performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH ARKG | -4.31%-3.25% | -6.56%+36.71% | +14.29%+76.72% | +30.94%+65.56% | +86.70%+132.21% | +44.35%-29.90% |
| Flows | XPH ARKG | -$80M+$37M | +$11M+$51M | +$186M+$90M | +$206M+$63M | +$160M-$431M | +$157M-$2.01B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH ARKG | +22.82%+49.99% | +23.36%+44.59% | +20.82%+44.73% | +21.10%+46.89% |
| Max drawdown | XPH ARKG | -16.58%-17.81% | -16.58%-27.52% | -23.45%-46.41% | -30.87%-76.56% |
| Max drawdown duration | XPH ARKG | 69d22d | 69d126d | 322d882d | 1452d1818d |
Trading data
XPH | ARKG | |
Last sale 10/28/2026 at 1:30 PM | $64.55 | $54.82 |
| Previous close 10/27/2026 | $63.96 | $51.65 |
| Consolidated volume 10/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexXPH | ARKG | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
XPH | ARKG | |
|---|---|---|
| Last price | $64.55 | $54.82 |
| 1D performance | +0.92% | +6.14% |
| AuM | $447.54 M | $2.18 B |
| E/R | 0.35% | 0.75% |
Characteristics
XPH | ARKG | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | State Street Investment Management | Ark Investment |
| Benchmark | S&P Pharmaceuticals Select Industry Index | - |
| N° of holdings | 62 | 31 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | April 2, 2019 |
| ESG | No | No |
Advertisement
Exposure
Countries
XPH
USA
89.77%
Other
10.23%
ARKG
USA
88.62%
Other
11.38%
Sectors
XPH
Healthcare
93.27%
Other
6.73%
ARKG
Healthcare
97.89%
Other
2.11%
Advertisement
Diversification
XPH
Total weight of top 15 holdings out of 15
34.13%
ARKG
Total weight of top 15 holdings out of 15
74.64%
Top 15 holdings
Data as of August 31, 2026
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
ARKG
10X Genomics, Inc.
9.58%
Twist Bioscience Corp.
9.13%
Tempus AI, Inc.
7.91%
CRISPR Therapeutics AG
6.10%
Personalis, Inc.
5.93%
Absci Corp.
4.88%
Natera, Inc.
4.06%
Illumina, Inc.
4.04%
Eli Lilly & Co.
3.86%
CareDx, Inc.
3.85%
Guardant Health, Inc.
3.81%
Beam Therapeutics, Inc.
3.56%
Compass Pathways Plc
3.17%
Recursion Pharmaceuticals, Inc.
2.44%
Adaptive Biotechnologies Corp.
2.32%
Frequently asked questions about XPH and ARKG
How have the XPH and ARKG ETFs performed in 2026?
As of October 27, 2026, XPH is up 14.29% year-to-date (YTD), while ARKG has returned 76.72%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: XPH or ARKG?
Year-to-date, the XPH ETF saw +$186M in flows, compared to +$90M for ARKG.
Which ETF is more volatile: XPH or ARKG?
Over the past year, XPH had a volatility of 23.36%, while ARKG experienced 44.59%.
Which ETF is bigger: XPH or ARKG?
As of October 27, 2026, XPH holds $447.54 M in assets under management (AUM), while ARKG manages $2.18 B.
What sectors do the XPH and ARKG ETFs invest in?
XPH leans toward sectors like Healthcare. Meanwhile, ARKG focuses on Healthcare.
What are the top holdings of the XPH ETF and ARKG ETF?
XPH top holdings include Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc.. ARKG holds in its top three: 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc..
Which ETF is more diversified: XPH or ARKG?
XPH holds 62 securities with 34.13% of its assets in the top 15. ARKG has 31 securities and a top 15 weight of 74.64%.
Advertisement
Latest news about XPH & ARKG
The Weekly ETF Market Monitor (October 19-23, 2026)
October 26, 2026
ARKG
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
Advertisement
Advertisement
